Navigation Links
WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
Date:8/23/2011

FREMONT, Calif., Aug. 23, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genomic analysis systems, announced today that it intends to file its Quarterly Report on Form 10-Q for the period ended June 30, 2011 within two weeks.  The company had previously filed a Form 12b-25 with the Securities and Exchange Commission relating to its Form 10-Q filing.  

In order to complete its financial statements and other information contained in the Quarterly Report on Form 10-Q, the company needs additional time to finalize the valuation amounts and related accounting treatment of convertible preferred stock, convertible notes and warrants issued on May 27, 2011 in the company's $30.6 million private placement financing.  

About WaferGen Biosystems, Inc. 

WaferGen Biosystems, Inc. develops, manufactures and sells state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries to advance next generation sequencing and ultimately personalized medicine.  WaferGen offers the breakthrough SmartChip Real-Time PCR System, a next-generation Real-Time PCR system for discovery and validation of gene expression patterns (biomarkers) on a single platform. For additional information, please see http://www.wafergen.com.

Forward Looking Statements

This press release contains certain "forward-looking statements" relating to the expected filing date of the company's Form 10-Q for the second quarter of 2011.  Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.   More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2010 and the company's most recent Quarterly Report on Form 10-Q for the period ended March 31, 2011.  Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov.  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

WaferGen Contacts
510-651-4450

Don Huffman, CFO
don.huffman@wafergen.com

Media:  Joyce Strand
joyce.strand@wafergen.com

Investors:  Tim Ryan
tryan@shorehamgroupllc.com
212-242-7777


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Announces Second Quarter 2008 Financial Results
2. WaferGen to Present at the Seventh Annual BIO Investor Forum
3. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
4. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
5. WaferGen Announces Third Quarter 2008 Financial Results
6. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
7. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
8. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference
9. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
10. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
11. WaferGen Announces Signing of Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental ... wide range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) ... NDD research and testing. , However, designing a custom panel for disease ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont ... strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont ... discovery, plant breeding, enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is ...
(Date:7/15/2017)... , ... July 15, 2017 , ... Cuvette ... years. During this time, the people at FFS have learned that their biggest ... engineers at FFS are able to launch new products to meet the changing needs ...
(Date:7/14/2017)... Cumberland Foreside, Maine (PRWEB) , ... July 13, ... ... its VALIDATE® D-Dimer linearity and calibration verification test kit has received US FDA ... D-Dimer kit, in a human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):